{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T19:22:34Z","timestamp":1773084154134,"version":"3.50.1"},"reference-count":37,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The utilization of eltrombopag (EPAG) in the management of post allogenic hematopoietic cell transplant (HCT) cytopenia has exhibited promising outcomes. Isolated thrombocytopenia and poor graft function (PGF) are factors that adversely influence transplant outcomes and patient well\u2010being. This retrospective study aims to assess EPAG efficacy in this context as a primary outcome and evaluate early EPAG tapering post complete response (CR) for cost efficiency and response durability as a secondary outcome. We analyzed 39 patients who underwent allogeneic HCT; EPAG was administered to 89.7% of patients for PGF and 10.3% for isolated thrombocytopenia. The overall response rate (ORR) after 4\u2009weeks of EPAG treatment was 71.8%, with 48.7% achieving a complete response (CR). Early tapering of EPAG post\u2010CR was explored for cost benefit among responders. Early tapering was defined as the start of tapering after 4\u2009weeks of achieving CR and was found to be associated with significant response durability with a trend towards cost effectiveness. Eltrombopag response was independent of megakaryocyte number or density prior to drug initiation. The study suggests EPAG as a safe treatment for PGF and isolated thrombocytopenia post\u2010allogeneic HCT and proposes early drug tapering as a potentially cost\u2010beneficial approach.<\/jats:p>","DOI":"10.1111\/ejh.70081","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T02:58:07Z","timestamp":1765767487000},"page":"311-318","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Eltrombopag in Treating Post\u2010Allogeneic Hematopoietic Stem Cell Transplantation Cytopenias: Efficacy, Response Durability, and Cost Benefit of Early Drug Tapering"],"prefix":"10.1111","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3584-5480","authenticated-orcid":false,"given":"Rawan","family":"Al\u2010Omari","sequence":"first","affiliation":[{"name":"Hans Messner Allogeneic Transplant Program Princess Margaret Cancer Centre  Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2333-4081","authenticated-orcid":false,"given":"Ram Vasudevan","family":"Nampoothiri","sequence":"additional","affiliation":[{"name":"Transplantation and Cellular Therapy Program Ottawa Hospital  Ottawa Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Sakhdari","sequence":"additional","affiliation":[{"name":"Department of Pathology Princess Margaret Cancer Centre  Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eshetu G.","family":"Atenafu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics Princess Margaret Cancer Centre  Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caden","family":"Chiarello","sequence":"additional","affiliation":[{"name":"Hans Messner Allogeneic Transplant Program Princess Margaret Cancer Centre  Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis D.","family":"Kim","sequence":"additional","affiliation":[{"name":"Hans Messner Allogeneic Transplant Program Princess Margaret Cancer Centre  Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjun","family":"Law","sequence":"additional","affiliation":[{"name":"Hans Messner Allogeneic Transplant Program Princess Margaret Cancer Centre  Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7595-0113","authenticated-orcid":false,"given":"Ivan","family":"Pasic","sequence":"additional","affiliation":[{"name":"Hans Messner Allogeneic Transplant Program Princess Margaret Cancer Centre  Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Novitzky\u2010Basso","sequence":"additional","affiliation":[{"name":"Hans Messner Allogeneic Transplant Program Princess Margaret Cancer Centre  Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Auro","family":"Viswabandya","sequence":"additional","affiliation":[{"name":"Hans Messner Allogeneic Transplant Program Princess Margaret Cancer Centre  Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fotios V.","family":"Michelis","sequence":"additional","affiliation":[{"name":"Hans Messner Allogeneic Transplant Program Princess Margaret Cancer Centre  Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Mattsson","sequence":"additional","affiliation":[{"name":"Hans Messner Allogeneic Transplant Program Princess Margaret Cancer Centre  Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4786-5699","authenticated-orcid":false,"given":"Rajat","family":"Kumar","sequence":"additional","affiliation":[{"name":"Hans Messner Allogeneic Transplant Program Princess Margaret Cancer Centre  Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,12,14]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409\u2010021\u201001227\u20108"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101076"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.05.036"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004537"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-02278-5_41"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004537"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-024-02251-0"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720961910"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.03.019"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2009.0029"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11051364"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705444"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2001.v7.pm11302549"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.12.003"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2020.07.006"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.01.027"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409\u2010019\u20100435\u20102"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-019-01194-7"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2008-0366"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26657"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.6.2162.bloodjournal8762162"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409\u2010021\u201001362\u20102"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-021-03153-3"},{"issue":"9","key":"e_1_2_12_25_1","article-title":"Eltrombopag for the Treatment of Allogeneic Hematopoietic Stem Cell Transplantation\u2010Related Poor Graft Function","volume":"15","author":"Arslan Davulcu E.","year":"2023","journal-title":"Cureus"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04106-2"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409\u2010019\u20100442\u20103"},{"key":"e_1_2_12_28_1","article-title":"PB2468: A Retrospective Study of Eltrombopag in Patients With Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"7","author":"Ma L.","year":"2023","journal-title":"Hema"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0649-6"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.02.004"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3017"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010014\u20102158\u20101"},{"key":"e_1_2_12_33_1","unstructured":"Canadian Blood Services \u201cBlood Component Cost Per Unit Summary\u2014Annual Report 2018\u20132019 \u201dhttps:\/\/annual2019.blood.ca\/pdfs\/CBS\u2010AR2019\u2010en.pdf."},{"key":"e_1_2_12_34_1","unstructured":"Canadian Agency for Drugs and Technologies in Health \u201cCDEC Final Recommendation\u2014Eltrombopag Olamine (Revolade\u2014GlaxoSmithKline Inc.) \u201dhttps:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/complete\/cdr_complete_SR0377_Revolade_Mar\u201023\u20102015_e.pdf."},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010155813"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.05.023"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107484"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.4274\/balkanmedj.galenos.2022.2022\u20102\u201048"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70081","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.70081","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T02:07:35Z","timestamp":1770862055000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,14]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1111\/ejh.70081"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70081","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,14]]},"assertion":[{"value":"2025-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}